Oncotelic’s Sapu Nano to Showcase Deciparticle Nanomedicine Platform at BIO-Europe Spring 2026

Oncotelic Therapeutics, Inc. (OTCQB: OTLC) announced that its subsidiary Sapu Nano will present its Deciparticle nanomedicine platform and clinical pipeline at BIO-Europe Spring 2026 on March 25, where it has been selected as a presenting company. The presentation will highlight the company’s next-generation drug delivery technology designed to improve therapeutic outcomes in oncology.

The company will showcase two lead candidates during the event. Sapu003 (Everolimus for Injection) is currently in Phase 1 clinical trials, while Sapu006 (Docetaxel for Injection) is entering Phase 1 studies. These developments represent significant steps in advancing nanomedicine applications for cancer treatment.

Oncotelic’s participation in BIO-Europe Spring 2026 comes as the company seeks strategic partnerships to advance development and commercialization of its technologies. The event serves as a platform for biotechnology companies to connect with potential partners and investors in the life sciences sector.

The company’s focus on improving drug delivery through nanotechnology has implications for enhancing therapeutic index and unlocking new clinical potential for established cancer treatments. This approach could potentially address limitations in current drug delivery methods and improve patient outcomes in oncology.

For investors seeking additional information about Oncotelic Therapeutics, the company maintains a newsroom at https://ibn.fm/OTLC where updates are regularly posted. The full press release announcing the BIO-Europe Spring 2026 presentation is available at https://ibn.fm/Slq47.

The presentation at BIO-Europe Spring 2026 represents an important opportunity for Oncotelic to demonstrate the potential of its Deciparticle platform to the international biotechnology community. As the company advances its clinical pipeline, this visibility could facilitate partnerships necessary for further development and eventual commercialization of its nanomedicine technologies.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Oncotelic’s Sapu Nano to Showcase Deciparticle Nanomedicine Platform at BIO-Europe Spring 2026.

The post Oncotelic’s Sapu Nano to Showcase Deciparticle Nanomedicine Platform at BIO-Europe Spring 2026 appeared first on citybuzz.